THE VASCULAR ENDOTHELIUM synthesizes prostacyclin, a potent antiaggregatory substance with vasodilator properties. It also activates (e.g., angiotensin I) or inactivates (e.g., bradykinin, serotonin) a number of vasoactive substances present in the blood (figure 1). Thus, it is far from being a passive diffusion barrier, but it can actively alter the amounts of vasoactive substances reaching the deeper layers of the blood vessel wall. In addition, endothelial cells can modulate powerfully the responsiveness of the vascular smooth muscle of the tunica media. Indeed, Furchgott and Zawadzkil first noted that rings of rabbit aorta, contracted with norepinephrine, would relax upon exposure to acetylcholine if they were handled carefully to preserve the endothelial layer; if the endothelium was simply mechanically rubbed off, no relaxation was seen. Similar findings have been obtained in a host of other blood vessels, including coronary arteries (figure 2), and with a variety of agents (figure 3).9-6 The prototypic response to acetylcholine probably is only a pharmacologic curiosity since endothelial cells are not innervated by cholinergic neurones, and any acetylcholine that would reach the blood would be degraded at once by circulating cholinesterases. However, the finding that a number of other substances present in the blood under normal or pathologic conditions can cause potent endothelium-dependent responses implies that such responses may play a role in health and disease. This article briefly discusses this possibility in regard to the interaction between platelets and endothelial cells (see references 7 and 8) .
Contractile responses to aggregating platelets. Cohen et al.9 10 observed that isolated rings of canine coronary artery contract if autologous platelets aggregate in the organ chamber in which the rings are suspended. Such contractions are markedly enhanced if the endothelium is removed ( figure 4 thromboxane synthetase inhibitor dazoxiben reduces the ischemic response to atrial pacing in subjects with coronary artery disease,2 suggesting that thromboxane A2 may contribute to constriction of coronary vessels even in the absence of overt spasm. Thromboxane B2 can be measured in the fluid from organ chambers where the interaction between aggregating platelets and isolated blood vessels are studied. 0 13 However, inhibitors of cyclooxygenase do not alter the response of coronary arteries to aggregating platelets.9 21 Thus, it seems unlikely that thromboxane A2 contributes to the endothelium-dependent response to the latter.
Adenine nucleotides. ADP and ATP are contained in large quantities in the dense granules of platelets and are released during aggregation. Both compounds cause similar endothelium-dependent relaxation in a at high concentrations ( figure 10 ). This relaxation is endothelium dependent, but it persists in the presence of CV-3988; 2-lyso-platelet-activating factor causes relaxation similar to that caused by platelet-activating factor. It seems unlikely, therefore, that endotheliumdependent relaxation is due to the interaction of platelet-activating factor with a receptor similar to those mediating platelet activation and hypotension. At the high concentrations required to observe it, a direct membrane effect of these lipids analogous to that observed with arachidonic and oleic acid32 is a more likely explanation. The synthesis of prostacyclin is not involved, since incubation of the blood vessels with the inhibitor of cyclooxygenase indomethacin does not block the response (figure 10). Unless very high local concentrations of platelet-activating factor (and 2-lyso-platelet-activating factor, which is also contained in platelets)33 are achieved at the sites of platelet aggregation, it is unlikely that these substances contribute directly to platelet-induced relaxation. relaxation, which overcomes the direct constrictor effect that it has on smooth muscle ( figure 1 1) . 23 24 35-37 The endothelium-dependent relaxation to thrombin is abolished but the direct contractile effect is augmented by hypoxia.36 37 An endothelium-dependent dilatation triggered by the platelet products (and thrombin) would tend to flush away the beginning aggregate before it could occlude the vessel ( figure 12) . If, on the other hand, the endothelium were absent, damaged, or for some reason failed to function properly, the response of the vessel to platelet products and thrombin would be contraction, as observed in the rings denuded of endothelium in vitro ( figure 12 ). Such contraction would further reduce the luminal area and increase the obstruction to blood flow.38 Clinical coronary arterial spasm may be just such a contraction. A potential pivotal role of the endothelium becomes apparent when one recalls that disruption of the endothelium by an atheromatous plaque is a ubiquitous feature of coronary disease, and that such plaques and partial obstructions can initiate platelet activation. It has been demonstrated that patients with classic and Prinzmetal's angina have increased coronary sinus levels of thromboxane B2 (the metabolite of the potent vasoconstrictor prostanoid produced by activated platelets, thromboxane A2) during atrial pacing, whereas normal subjects do not,39 40 
